Was there a thrombotic microangiopathy?

Czech version

Authors: Z. Stašková ^1,2; Š. Ožanová ^1,2; K. Balošáková ^1,2; J. Václavík ^1,2
Published in: Transfuze Hematol. dnes,31, 2025, No. 2, p. 103-107.
Category: Case Reports
doi: https://doi.org/10.48095/cctahd2025prolekare.cz10

Overview

Thrombotic microangiopathies represent a heterogeneous group of diseases of various aetiology, whose common feature is damage to the endothelium of small blood vessels. Typical laboratory findings include thrombocytopenia and microangiopathic haemolytic anaemia, along with signs of organ damage (most commonly affecting the kidneys). In the differential diagnosis, it is necessary to differentiate, among other conditions, autoimmune diseases with multi-organ failure. This case report presents a case of the young woman who developed multi-organ failure in the early postpartum period. For this patient, it was the first manifestation of systemic lupus erythematosus. Despite prompt diagnosis and treatment, the course of hospitalization was complicated – both due to the underlying disease and due to severe infections, that required adjustments to her immunosuppressive therapy. The patient was discharged to outpatient care after nearly four months of intensive treatment, and her condition continues to improve.

Keywords:

Systemic lupus erythematosus – thrombotic microangiopathies – multi-organ failure

Sources

1. George JN, Nester CM, McIntosh JJ. Syndromes of thrombotic microangiopathy associated with pregnancy. Hematology Am Soc Hematol Educ Program. 2015; 2015: 644–648.

2. Seeman T, Podracká Ľ, Štolbová Š, et al. Trombotické mikroangiopatie – hemolyticko-uremické syndromy a trombotická trombocytopenická purpura. Čes-slov Pediat. 2017; 72 (2): 99–108.

3. Dao KH, Bermas BL. Systemic lupus erythematosus management in pregnancy. Int J Womens Health. 2022; 14: 199–211. doi: 10.2147/IJWH.S282604.

4. Zamani B, Shayestehpour M, Esfahanian F, et al. The study of factors associated with pregnancy outcomes in patients with systemic lupus erythematosus. BMC Res Notes. 2020; 13: 185. doi: 10.1186/s13104-020-05039-9.

5. Horák P, Tichý T, Systémové onemocnění pojiva. In: Pavelka K, Vencovský J, Horák P, et al. Revmatologie, 2. aktualizované a rozšířené vydání, Maxdorf, 2018; 433–461.

6. Shenkman B, Einav Y. Thrombotic thrombocytopenic purpura and other thrombotic microangiopathic hemolytic anemias: diag- nosis and classification. Autoimmun Rev. 2014; 13: 584–586.

7. Shah AA, Higgins JP, Chakravarty EF. Thrombotic microangiopathic hemolytic anemia in a patient with SLE: diagnostic difficulties. Nat Clin Pract Rheumatol. 2007; 3: 357–362.

8. Crawley JTB, Scully MA. Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies. Hematology Am Soc Hematol Educ Program. 2013; 2013: 292–299.

9. Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024; 83: 15–29.

Podíl autorů na přípravě rukopisu

ZS – napsání rukopisu, léčba nemocné

KB – léčba nemocné

ŠO – léčba nemocné, kontrola, revize rukopisu

JV – kontrola, revize rukopisu

Konflikt zájmů

Autoři práce prohlašují, že v souvislosti s tématem, vznikem a publikací tohoto článku nejsou ve střetu zájmů a vznik ani publikace článku nebyly podpořeny žádnou farmaceutickou firmou.

Autor prohlašuje, že v souvislosti se vznikem a tématem článku nebyl v uplynulých 24 měsících smluvně vázán se žádnou farmaceutickou společností ani neobdržel finanční podporu pro provedení práce a publikaci.

Do redakce doručeno dne: 27. 3. 2025.

Přijato po recenzi dne: 21. 4. 2025.

MUDr. Stašková Zuzana

Interní a kardiologická klinika

FN Ostrava

17. listopadu 1790/5

708 52 Ostrava-Poruba

e-mail: zuzana.staskova@fno.cz